Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionPrudential Financial Inc
Latest Disclosed Ownership18,608 shares
Latest Disclosed Value $ 1,202,635
Prudential Financial Inc reports 3.02% decrease in ownership of HALO / Halozyme Therapeutics, Inc.

On May 13, 2026 - Prudential Financial Inc filed a 13F-HR form disclosing ownership of 18,608 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $1,202,635 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 19,188 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of -3.02% during the quarter. The current value of the position is $1,331,030 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 18,608 -580 -3.02 1,203 -6.89 0.0015
2026-02-13 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 19,188 -49,483 -72.06 1,291 -74.36 0.0016
2025-11-13 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 68,671 -89,265 -56.52 5,036 -38.70 0.0060
2025-08-12 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 157,936 -30,190 -16.05 8,216 -31.56 0.0106
2025-05-13 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 188,126 -35,162 -15.75 12,004 12.45 0.0171
2025-02-11 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 223,288 -7,275 -3.16 10,675 -19.11 0.0146
2024-11-14 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 230,563 49,892 27.61 13,197 39.52 0.0186
2024-08-13 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 180,671 -42,534 -19.06 9,460 4.19 0.0142
2024-05-14 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 223,205 85,465 62.05 9,080 78.37 0.0128
2024-02-13 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 137,740 95,128 223.24 5,091 212.85 0.0077
2023-11-13 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 42,612 22,144 108.19 1,628 120.46 0.0026
2023-08-11 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 20,468 -2,072 -9.19 738 -26.35 0.0011
2023-05-12 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 22,540 336 1.51 1,003 -20.67 0.0016
2023-02-14 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 22,204 -22,672 -50.52 1,263 -28.85 0.0021
2022-11-04 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 44,876 -270,353 -85.76 1,775 -87.21 0.0030
2022-08-15 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 315,229 229,934 269.58 13,876 307.88 0.0220
2022-05-13 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 85,295 -24,989 -22.66 3,402 -23.29 0.0045
2022-02-14 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 110,284 -940 -0.85 4,435 -2.10 0.0055
2021-11-15 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 111,224 31,607 39.70 4,530 25.28 0.0063
2021-08-16 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 79,617 40,331 102.66 3,616 120.76 0.0050
2021-05-12 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 39,286 -241,958 -86.03 1,638 -86.36 0.0025
2021-08-16 2020-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 0042 40637H109 281,244 277,958 8,458.86 12,010 13,865.12 0.0202
2021-02-16 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 281,244 277,958 12,012 0.0202
2021-08-05 2020-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 3,286 2,658 423.25 86 405.88 0.0124
2020-11-16 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 159,187 158,559 4,183 0.0079
2021-08-05 2020-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 0026 40637H109 628 390 163.87 17 325.00 0.0031
2020-08-12 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 343,517 343,279 9,209 0.0177
2021-08-05 2020-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 0017 40637H109 238 5 2.15 4 0.00 0.0010
2020-05-12 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 443,727 443,494 7,983 0.0177
2021-08-05 2019-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 0017 40637H109 233 0 0.00 4 0.00 0.0010
2020-02-11 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 351,290 351,057 6,228 0.0092
2021-08-05 2019-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 0015 40637H109 233 -16,483 -98.61 4 -98.61 0.0013
2019-11-13 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 26,135 9,419 405 0.0006
2019-08-08 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 16,716 3,750 28.92 287 37.32 0.0004
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 12,966 160 1.25 209 11.76 0.0003
2019-02-07 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 12,806 -320,076 -96.15 187 -96.91 0.0003
2018-11-07 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 332,882 -760,248 -69.55 6,048 -67.20 0.0089
2018-08-13 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,093,130 -302,060 -21.65 18,441 -32.53 0.0276
2018-05-04 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,395,190 485,904 53.44 27,332 48.37 0.0416
2018-02-13 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 909,286 896,610 7,073.29 18,422 8,273.64 0.0251
2017-11-02 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 12,676 950 8.10 220 46.67 0.0004
2017-08-07 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 11,726 940 8.72 150 7.14 0.0002
2017-05-10 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 10,786 0 0.00 140 30.84 0.0002
2017-02-07 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 10,786 -1,100 -9.25 107 -25.69 0.0002
2016-11-04 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 11,886 720 6.45 144 50.00 0.0002
2016-08-09 2016-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 11,166 -91,200 -89.09 96 -90.09 0.0002
2016-05-09 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 102,366 -559,800 -84.54 969 -91.56 0.0017
2016-02-12 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 662,166 185,100 38.80 11,475 79.10 0.0208
2015-11-10 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 477,066 335,100 236.04 6,407 99.84 0.0126
2015-08-06 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 141,966 111,300 362.94 3,206 631.96 0.0057
2015-05-01 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 30,666 19,500 174.64 438 305.56 0.0008
2015-02-06 2014-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,166 -1,400 -11.14 108 -5.26 0.0002
2014-11-12 2014-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 12,566 -12,123 -49.10 114 -53.28 0.0002
2014-08-13 2014-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 24,689 12,563 103.60 244 58.44 0.0004
2014-05-14 2014-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 12,126 300 2.54 154 -12.99 0.0003
2014-02-11 2013-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,826 -2,800 -19.14 177 9.94 0.0004
2013-11-07 2013-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 14,626 300 2.09 161 41.23 0.0003
2013-08-07 2013-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 14,326 14,326 114 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.